{"id":"W4414379673","doi":"10.1093/oncolo/oyaf270","title":"Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Université du Québec à Montréal","funders":"Genentech; Servier; European Society for Medical Oncology; Eisai; Verastem Oncology; Clovis Oncology; Astellas Pharma; Novocure; Regeneron Pharmaceuticals; Amgen; Mereo BioPharma; Pfizer; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Mersana Therapeutics; PTC Therapeutics; GlaxoSmithKline","keywords":"Clinical trial; Ovarian cancer; Immunotherapy; Bevacizumab; PARP inhibitor; Phases of clinical research; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005413538,0.0007934773,0.002665219,0.0009039771,0.0004009003,0.001707739,0.001007882,0.001532871,0.008280955],"category_scores_gemma":[0.007111146,0.0003344307,0.003872051,0.001200527,0.0004768405,0.0009879369,0.0005182793,0.00186836,0.0007469556],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001607813,"about_ca_system_score_gemma":0.002876541,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008063402,"about_ca_topic_score_gemma":0.003470718,"domain_scores_codex":[0.9982565,0.0009588092,0.0003240974,0.0001695515,0.0001759229,0.0001152054],"domain_scores_gemma":[0.9973883,0.0009922986,0.000984938,0.0001018804,0.0002928218,0.0002397068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4128605,0.005288752,0.004028848,0.2060285,0.03113505,0.0005661261,0.0004164588,0.001784857,0.01219782,0.001907913,0.02043703,0.3033482],"study_design_scores_gemma":[0.7444893,0.08929599,0.01157391,0.03034981,0.04095619,0.001106744,0.0002520687,0.001152007,0.004066611,0.002423673,0.07423354,0.0001001854],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2252387,0.6762741,0.002981488,0.006749857,0.002418655,0.05138758,0.01291623,0.0004628178,0.02157068],"genre_scores_gemma":[0.5971559,0.3104005,0.009748241,0.0123205,0.001027334,0.04726579,0.01246726,0.000130393,0.009484055],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.008280955,"threshold_uncertainty_score":0.02862984,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2927783521745961,"score_gpt":0.5819201111673444,"score_spread":0.2891417589927484,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}